These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27717544)

  • 61. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
    Pramanik SD; Kumar Halder A; Mukherjee U; Kumar D; Dey YN; R M
    Front Chem; 2022; 10():948217. PubMed ID: 36034650
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
    Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y
    Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
    Chan AM; Fletcher S
    RSC Med Chem; 2021 Mar; 12(2):178-196. PubMed ID: 34046608
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The emerging role of SPOP protein in tumorigenesis and cancer therapy.
    Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
    Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
    Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
    Jadhavar PS; Ramachandran SA; Riquelme E; Gupta A; Quinn KP; Shivakumar D; Ray S; Zende D; Nayak AK; Miglani SK; Sathe BD; Raja M; Farias O; Alfaro I; Belmar S; Guerrero J; Bernales S; Chakravarty S; Hung DT; Lindquist JN; Rai R
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5222-5228. PubMed ID: 27717544
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drugging the HDAC6-HSP90 interplay in malignant cells.
    Krämer OH; Mahboobi S; Sellmer A
    Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90).
    Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G
    Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.